Beneve LLC has secured exclusive U.S. network marketing and direct sales rights for BIOMEnd™, a patented L-lysine butyrate ingredient designed to support digestive and gut health. The agreement gives Beneve exclusive access to distribute the ingredient through direct selling channels across the United States.
This strategic partnership strengthens Beneve’s commitment to science-backed wellness products and premium ingredient innovation.
BIOMEnd™ is an advanced butyrate delivery ingredient developed to support digestive wellness and intestinal health. It contains butyric acid, a naturally occurring short-chain fatty acid produced by the gut microbiome.
Researchers have increasingly focused on butyric acid because of its role in maintaining gut barrier integrity, supporting microbial balance, and promoting overall digestive health. It may also help support the body’s natural GLP-1 activity, making it an important ingredient in modern gut health solutions.
BIOMEnd utilizes patented L-lysine butyrate technology that enhances the absorption and utilization of butyric acid in dietary supplements.
According to available clinical research, BIOMEnd delivers five times greater oral bioavailability than tributyrin and demonstrates superior absorption compared to sodium butyrate. These advantages position BIOMEnd among the most advanced butyrate delivery systems currently available in the supplement industry.
Published research highlighting the ingredient’s bioavailability has also appeared in the Journal of Exercise and Nutrition.
Beneve has incorporated BIOMEnd into its flagship gut health supplement, Gut Advantage (G3). The formula is designed as a comprehensive gut support system that combines multiple health-promoting ingredients.
The product includes:
Together, these ingredients create a multi-layered approach to digestive health, microbiome balance, and overall gut function.
The addition of BIOMEnd aligns with Beneve’s broader product development strategy. The company focuses on premium ingredient sourcing, clinically supported technologies, and evidence-based formulations.
Rather than relying on generic supplements, Beneve continues to invest in branded ingredients and scientifically supported wellness solutions that offer meaningful differentiation in the market.
The exclusivity agreement also highlights Beneve’s collaboration with Nutrashure, the company behind BIOMEnd. Both organizations share a commitment to innovation, long-term wellness, and consumer-focused product development.
This partnership supports Beneve’s mission of promoting physical, mental, and financial well-being through its “People Doing Good Together” philosophy.
Consumer interest in microbiome health and digestive wellness continues to grow worldwide. As a result, butyric acid supplementation has become an increasingly important category within the nutritional industry.
With exclusive U.S. direct sales rights to BIOMEnd, Beneve is positioning itself ahead of many generic gut health brands. The company’s strategy focuses on proprietary ingredient technology, scientific validation, and product differentiation rather than competing solely on branding.
By leveraging advanced butyrate delivery technology and clinically supported formulations, Beneve aims to strengthen its leadership position in the rapidly expanding gut health market.
Â
There are no reviews yet. Be the first one to write one.
